

# Cecilia Yeung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/860812/publications.pdf>

Version: 2024-02-01

17  
papers

1,469  
citations

933447

10  
h-index

996975

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

568  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
2	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
3	Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 176-179.	2.0	39
4	The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy. <i>PLoS ONE</i> , 2014, 9, e107817.	2.5	27
5	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
6	Prevalence of Chromosomally Integrated Human Herpesvirus 6 in Patients with Human Herpesvirus 6 Central Nervous System Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 371-373.	2.0	22
7	Comparison of four next generation sequencing platforms for fusion detection: OncoPrint by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. <i>Cancer Genetics</i> , 2020, 243, 11-18.	0.4	22
8	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
9	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€¢CBF) Tj ETQq1 1 0.784314 rg	2.8	17
10	Targeting an alternate Wilmsâ€™ tumor antigen 1 peptide bypasses immunoproteasome dependency. <i>Science Translational Medicine</i> , 2022, 14, eabg8070.	12.4	12
11	Jumping translocations in myelodysplastic syndromes. <i>Cancer Genetics</i> , 2016, 209, 395-402.	0.4	7
12	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 38-39.	1.4	7
13	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
14	Mutational profiling in acute lymphoblastic leukemia by RNA sequencing and chromosomal genomic array testing. <i>Cancer Medicine</i> , 2021, 10, 5629-5642.	2.8	3
15	Disruption of Iron Regulation after Radiation and Donor Cell Infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1173-1181.	2.0	1
16	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy. <i>Blood</i> , 2017, 130, 805-805.	1.4	0
17	PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 8610-8618.	0.5	0